Scholars Central

Conference abstractPublished 2012

Insulin, cardiovascular disease and malignancy, where do we stand?

Authors: GR Sridhar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The major randomized clinical trials assessing the effects of vascular disease and glycemic control (DCCT and UKPDS) have shown that tight glycemic control prevents or postpones the onset of microvasular disease (retinopathy, neuropathy, nephropathy). Death and disability from diabetes however result mainly from macrovascular disease, for which coronary artery disease (CAD) is a major contributor. The evidence for glycemic control and CAD was less forthcoming, falling just short of statistical and clinical significance. A series of studies were therefore carried out to see whether really tight glycemic control would make a difference to the occurrence of CAD. It did, but not in the direction one anticipated. A large scale trial compared the effect of achieving euglycemia on the occurrence of coronary events in elderly people with a risk of vascular disease. It had to be prematurely terminated because those in the intensive treatment arm who had lower glycosylated hemoglobin were found to have more number of coronary events. The results of the ORIGIN trial, published early this year showed that CAD was not prevented by euglycemia, but to allay the suspicions raised by ACCORD trial, showed that it was not increased either. Similarly, the association of insulin analogs with cancer made a dramatic appearance based on epidemiological studies. There is well known risk of some forms of cancer with diabetes, and vice versa. Also, in our glucose-centric view of insulin action, its effect on cell proliferation via insulin like growth factor has been overlooked. A Lancet consensus statement gave clinical guidelines that the use of insulin should not be deterred by the possible risk of future malignancy, although those with cancer or at risk need to be carefully evaluated about the use of insulin. In addition patients with diabetes mellitus should also be monitored for the occurrence of cancer. The ORIGIN study, which was caught by the insulin analog-cancer imbroglio also found that those using cancer did not have a greater prevalence of cancer in the period under follow up.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Diabetes & Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “GR Sridhar”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels